Prosecution Insights
Prosecution Insights
15 pending office actions • 10 clients • 15 examiners • 13 art units • 0 of 15 (0%) have an AI response strategy ready • 18 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 7 (47%) |
| §102 only | 1 (7%) |
| §112 only | 1 (7%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 3 (20%) |
| Multi-statute (no §101) | 2 (13%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.8% | +19.6% |
| CHENG, KAREN | 1 | 76.5% | +27.3% |
| BORI, IBRAHIM D | 1 | 44.2% | +38.7% |
| BREDEFELD, RACHAEL EVA | 1 | 27.5% | +34.8% |
| SZNAIDMAN, MARCOS L | 1 | 37.2% | +16.0% |
| PIHONAK, SARAH | 1 | 61.1% | +42.9% |
| CHHAY, BONIRATH | 1 | 100.0% | +0.0% |
| FISCHER, JOSEPH | 1 | 43.3% | +45.9% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.0% |
| SALVOZA, M FRANCO G | 1 | 68.9% | +29.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555103 | A COMBINATION COMPRISING A SPECIFIC HDAC6 INHIBITOR AND AT LEAST ONE CTLA4 CHECKPOINT INHIBITOR | CHHAY, BONIRATH | 13d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18317386 | ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 | SALVOZA, M FRANCO G | 155d overdue |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | BREDEFELD, RACHAEL EVA | — |
| 18580322 | BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTIASTHMATIC AGENT | SZNAIDMAN, MARCOS L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18317386 | ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 | SALVOZA, M FRANCO G | 155d overdue |
| 18816347 | HYDROGEN SULFATE SALT OF A BCL-2 INHIBITOR, RELATED CRYSTALLINE FORM, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | WHITE, DAWANNA SHAR-DAY | — |
| 18702363 | TRIMETAZIDINE SALTS | CHENG, KAREN | — |
| 18692906 | OXADIAZASPIRO COMPOUNDS FOR USE IN THE TREATMENT OF MOTONEURON DEGENERATION OR IN NEUROPROTECTION | BORI, IBRAHIM D | — |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | BREDEFELD, RACHAEL EVA | — |
| 18580322 | BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTIASTHMATIC AGENT | SZNAIDMAN, MARCOS L | — |
| 18579645 | PROCESS FOR THE PREPARATION OF BUDESONIDE 21-PHOSPHATE | PIHONAK, SARAH | — |
| 18554511 | TREATMENT OF NEUROPATHIC CORNEAL PAIN WITH NGF | FISCHER, JOSEPH | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Servier | 3 |
| ESTEVE PHARMACEUTICALS, S.A. | 3 |
| Genetic S.p.A. | 2 |
| Vernalis (R&D) Ltd. | 1 |
| Axsome Therapeutics | 1 |
| Italfarmaco | 1 |
| TUFTS MEDICAL CENTER, INC. | 1 |
| Novartis | 1 |
| SEMENTIS LIMITED | 1 |
| NATIONAL UNIVERSITY OF IRELAND, GALWAY | 1 |
| Art Unit | Apps |
|---|---|
| 1623 | 2 |
| 1629 | 1 |
| 3786 | 1 |
| 1628 | 1 |
| 1627 | 1 |
| 1645 | 1 |
| 1658 | 1 |
| 1625 | 1 |
| 1672 | 1 |
| 1693 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18816347 | HYDROGEN SULFATE SALT OF A BCL-2 INHIBITOR, RELATED CRYSTALLINE FORM, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Vernalis (R&D) Ltd. | WHITE, DAWANNA SHAR-DAY | §103§112DP | Non-Final OA | — | Pending | Aug 27, 2024 | |
| 18702363 | TRIMETAZIDINE SALTS | Les Laboratoires Servier | CHENG, KAREN | 1623 | §103 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18692906 | OXADIAZASPIRO COMPOUNDS FOR USE IN THE TREATMENT OF MOTONEURON DEGENERATION OR IN NEUROPROTECTION | Esteve Pharmaceuticals, S.A. | BORI, IBRAHIM D | 1629 | §103DP | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18687962 | METHODS AND COMPISITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCUALR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | Axsome Therapeutics, Inc. | BREDEFELD, RACHAEL EVA | 3786 | §103 | Final Rejection | — | Pending | Feb 29, 2024 |
| 18580322 | BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTIASTHMATIC AGENT | Genetic S.p.A. | SZNAIDMAN, MARCOS L | 1628 | §102§103 | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18579645 | PROCESS FOR THE PREPARATION OF BUDESONIDE 21-PHOSPHATE | Genetic S.p.A. | PIHONAK, SARAH | 1627 | §103 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18555103 | A COMBINATION COMPRISING A SPECIFIC HDAC6 INHIBITOR AND AT LEAST ONE CTLA4 CHECKPOINT INHIBITOR | Italfarmaco Spa | CHHAY, BONIRATH | 1645 | §103Other | Final Rejection | 13d | Pending | Oct 12, 2023 |
| 18554511 | TREATMENT OF NEUROPATHIC CORNEAL PAIN WITH NGF | Tufts Medical Center, Inc. | FISCHER, JOSEPH | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Oct 09, 2023 |
| 18551033 | NEW PROCESS FOR THE SYNTHESIS OF 5-{5-CHLORO-2-[(3S)-3-[(MORPHOLIN-4-YL)METHYL]-3,4-DIHYDROISOQUINOLINE-2(1H)- CARBONYL]PHENYL}-1,2-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND ITS APPLICATION FOR THE PRODUCTION OF PHARMACEUTICAL COMPOUNDS | Novartis AG | SEAMAN, D MARGARET M | 1625 | §102 | Non-Final OA | 34d | Pending | Sep 18, 2023 |
| 18317386 | ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 | Sementis Limited | SALVOZA, M FRANCO G | 1672 | §103§112 | Final Rejection | 155d overdue | Pending | May 15, 2023 |
| 18004468 | DIOSMIN PREPARATION METHOD | Les Laboratoires Servier | LEE, HOI YAN NMN | 1693 | §103 | Final Rejection | — | Pending | Jan 06, 2023 |
| 17998368 | PARA-AMINO-BENZYL LINKERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CONJUGATES | Les Laboratoires Servier | VAN DRUFF, SYDNEY | 1643 | §103 | Final Rejection | — | Pending | Nov 10, 2022 |
| 17968253 | CO-CRYSTALS OF TRAMADOL AND COXIBS | Esteve Pharmaceuticals, S.A. | LEE, WILLIAM Y | 1623 | DP | Final Rejection | — | Pending | Oct 18, 2022 |
| 17336491 | COMPOSITIONS COMPRISING TRAMADOL AND CELECOXIB IN THE TREATMENT OF PAIN | Esteve Pharmaceuticals, S.A. | ORWIG, KEVIN S | 3991 | §103Other | Non-Final OA | 89d overdue | Pending | Jun 02, 2021 |
| 16632453 | STENTED VALVE | National University Of Ireland, Galway | WOZNICKI, JACQUELINE | 3774 | §112 | Non-Final OA | 85d | Pending | Jan 20, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial